Remote Ischemic Preconditioning (RIPC) modifies the plasma proteome in children undergoing repair of tetralogy of fallot: A randomized controlled trial

Abstract

Background: Remote ischemic preconditioning (RIPC) has been applied in paediatric cardiac surgery. We have demonstrated that RIPC induces a proteomic response in plasma of healthy volunteers. We tested the hypothesis that RIPC modifies the proteomic response in children undergoing Tetralogy of Fallot (TOF) repair. Methods and Results: Children (n=40) were randomized to RIPC and control groups. Blood was sampled at baseline, after cardiopulmonary bypass (CPB) and 6, 12 and 24h post-CPB. Plasma was analysed by liquid chromatography mass spectrometry (LC-MS) in an untargeted approach. Peptides demonstrating differential expression (p <0.01) were subjected to tandem LC-MS/MS and protein identification. Corresponding proteins were identified using the NCBI protein database. There was no difference in age (7.3± 3.5vs6.8±3.6 months)(p=0.89), weight (7.7 ±1.8vs7.5±1.9 kg)(p=0.71), CPB time (104±7vs94±7 min)(p=0.98) or aortic cross-clamp time (83±22vs75±20 min)(p=0.36). No peptides were differentially expressed at baseline or immediately after CPB. There were 48 peptides with higher expression in the RIPC group 6h post-CPB. This was no longer evident at 12 or 24h, with one peptide down-regulated in the RIPC group. The proteins identified were: inter-alpha globulin inhibitor (42.0±11.8 vs 820.8 ±181.1, p=0.006), fibrinogen preproprotein (59.3±11.2 vs 1192.6±278.3, p=0.007), complement-C3 precursor (391.2 ±160.9 vs 5385.1 ±689.4, p=0.0005), complement C4B (151.5±17.8 vs 4587.8 ±799.2, p=0.003), apolipoprotein B100 (53.4 ±8.3 vs 1364.5±278.2, p=0.005) and urinary proteinase inhibitor (358.6± 74.9 vs 5758.1± 1343.1, p=0.009). These proteins are involved in metabolism, haemostasis, immunity and inflammation. Conclusions: We provided the first comprehensive analysis of RIPC-induced proteomic changes in children undergoing surgery. The proteomic changes peak 6h post-CPB and return to baseline within 24h of surgery. Trial Registration: ACTR.org.au ACTRN12610000496011